Avapag 20mg Tablet (Avatrombopag)
Prescription RequiredManufactured By
Everest
Pack Of
28
Salt Composition
Avatrombopag
Storage
Keep in cold place
ALL SUBSTITUTES
Doptelet 20mg Tablet
Overview
Avapag 20mg Tablet contains Avatrombopag. Avapag tablet is a thrombopoietin receptor agonist. Treatment of thrombocytopenia in adults with chronic liver disease scheduled for a procedure, and chronic immune thrombocytopenia in patients with insufficient response to previous therapy, according to the selected treatment setting.
Avatrombopag 20mg tablet stimulates the thrombopoietin receptor on megakaryocyte progenitors, promoting platelet production. It is not an immediate platelet transfusion substitute. The exact strength and presentation matter for safe dosing; patients should follow the treating specialist’s plan and should not substitute a different strength or formulation without review.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | avapag |
| Generic / Active Ingredient | Avatrombopag |
| Strength | 20 |
| Dosage Form | Tablet |
| Manufacturer / Marketer | Everest |
| Pack Size | 28 |
| Prescription Required | Yes |
| Therapeutic Categories | Cancer Medicines |
| Uses | Lung Cancer, Colorectal Cancer |
Uses and Indications
Avatrombopag 20mg tablet is administered for the management of thrombocytopenia in adults under the following therapeutic settings:
- Thrombocytopenia in adults with chronic liver disease who are due to undergo surgery
- Chronic immune thrombocytopenia (ITP) in individuals whose prior treatment has been inadequate
The administration of Avapag 20mg will depend on the diagnosis, nature of the condition, ongoing medications, laboratory reports, and expert opinion. Avapag 20mg Tablet is not meant as an alternative to medical consultation or other supportive care needed for the primary disorder.
How Avapag 20mg Tablet Works
Avatrombopag tablet acts on thrombopoietin receptors found in megakaryocyte progenitor cells that are responsible for the formation of platelets. This mechanism works to help stimulate the production of more platelets. However, since it works by increasing the platelet production of the body rather than giving direct platelet transfusions, it cannot immediately be used as a substitute for platelet transfusion therapy. However, It is reliant on proper dosing according to the specific condition.
Clinical Evidence for Avapag 20mg Tablet
Avatrombopag 20mg clinical trials yielded the following results:
- ADAPT-1 and ADAPT-2: Treatment with Avapag 20 mg Tablet resulted in fewer platelet transfusions or rescue interventions than the placebo in adult patients with chronic liver disease, thrombocytopenia, and upcoming procedure.
- Chronic ITP: Clinical trials produced responses with platelet levels that could be sustained during therapy.
The above information is related to the Avatrombopag tablet compound and not to the proof of efficacy of the Avapag 20mg brand. This should be taken into account when assessing the data.
Side Effects of Avapag 20mg Tablet
Some patients might have adverse reactions to Avatrombopag 20mg. The nature and degree of the adverse reaction will depend on the circumstances of the use of the drug.
Common Side Effects
Commonly reported side effects may include:
- Headache
- Fatigue
- Nausea
- Abdominal discomfort
- Bruising
- Infections
Serious Side Effects
Serious side effects may require prompt medical attention. These can include:
- Blood clots or thrombotic events
- Significant changes in platelet counts that may increase the risk of clotting or bleeding
- Serious allergic reactions
Not all patients experience side effects. If symptoms persist or become significant, they should be reported to the healthcare provider.
Critical Safety Warning
Avapag Tablet should receive proper monitoring since an increase in platelet counts to too much could lead to the development of blood clots.
- Blood clots and thromboembolic events such as portal vein thrombosis can happen.
- The platelet count must not exceed the required amount needed to meet the objective of therapy.
- A patient should not attempt to normalize or increase platelet counts by themselves.
- Prompt medical assessment is needed for any signs of a severe allergic reaction, rash, bleeding, or the possibility of developing blood clots.
- A patient should report jaundice or other serious/unusual symptoms immediately.
It is important that no changes be made to the treatment regimen without consulting the healthcare provider.
Avapag 20mg Tablet Dosage and How To Take It
| Clinical situation | Dose |
|---|---|
| Unit strength | 20mg per tablet |
| Administration | Chronic liver disease: baseline platelets below 40 × 10⁹/L: 60mg (three tablets) once daily for 5 days; 40 to below 50 × 10⁹/L: 40mg (two tablets) once daily for 5 days. Start 10–13 days before procedure; procedure 5–8 days after last dose. Chronic ITP: commonly start 20mg once daily with food, then titrate based on platelet response; dosing and maximum schedule depend on clinical response and interacting drugs. |
| Route | Oral |
| Dose changes | Only on the treating clinician’s instructions. |
Avapag 20mg Tablet Missed Dose
In case of a missed dose of Avapag 20 mg, patients are advised to contact their treatment provider or consult the product information leaflet regarding the missed dose. It is important not to double the dose in an attempt to compensate for the missed one. In cases of chronic liver diseases, treatment is dependent on the timing of the planned intervention, hence the strict adherence to the dosing schedule and monitoring.
Safety Advice for Avapag 20mg Tablet
| Category | Status | Guidance |
|---|---|---|
| Pregnancy | High caution | A specialist assessment needs to be conducted before the use of Avapag 20 mg Tablet during pregnancy, taking into account the potential risks and benefits for the individual patient. |
| Breastfeeding | High caution | A specialist assessment needs to be conducted before the use of Avatrombopag 20mg during breastfeeding, taking into account the potential risks and benefits. |
| Liver / kidney function | Monitor | Liver and kidney function need to be assessed if it is related to the drug and the medical condition of the patient. |
| Interactions | Monitor | All prescription drugs, non-prescription medicines, nutritional supplements, and herbal products need to be informed to the healthcare provider. |
| Blood clots | Monitor | It is imperative to monitor patients for signs that might suggest any clotting problems or thromboembolic events. |
| Adjustment | Avoid | One should not alter the dosage or discontinue treatment abruptly without following the instructions provided by the physician. |
| Platelets count | Monitor | In cases of chronic liver diseases, one must check the platelet levels both before treatment and during the procedure. In chronic ITP cases, one needs to measure platelet counts weekly until stabilized, thereafter once monthly and once weekly for four weeks post treatment cessation. |
Monitoring During Avapag 20mg Tablet Treatment
- Platelet count should be evaluated before treatment and before the intended procedure in patients with chronic liver disease.
- In chronic ITP, platelet count should be assessed weekly until it stabilizes.
- Once it stabilizes, the assessment is done monthly.
- Weekly platelet count should be taken for at least four weeks following cessation of treatment in chronic ITP.
Monitoring should also take into consideration the presence of symptoms which could indicate formation of blood clots or any other serious problem.
Avapag 20mg Tablet Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Molecule | Avatrombopag |
| Strength | 20mg per tablet |
| Dosage form | Oral tablet |
| Class | Thrombopoietin receptor agonist |
| Uses | Treatment of thrombocytopenia in adults with chronic liver disease before a procedure, and chronic immune thrombocytopenia with inadequate response to previous therapy |
| How to take | Chronic liver disease: baseline platelets below 40 × 10⁹/L: 60mg (three tablets) once daily for 5 days; 40 to below 50 × 10⁹/L: 40mg (two tablets) once daily for 5 days. Start 10–13 days before procedure; procedure 5–8 days after last dose. Chronic ITP: commonly start 20mg once daily with food, then titrate based on platelet response; dosing and maximum schedule depend on clinical response and interacting drugs. |
| Key warning | Thrombotic and thromboembolic complications including portal-vein thrombosis; avoid attempting to normalize platelet count. |
Avapag 20mg Tablet Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Moderate or strong dual CYP2C9 and CYP3A4 inhibitors | Can increase exposure to Avatrombopag 20mg tablet and can impact the safety of the treatment regimen or need for dose adjustments for ITP. | It is recommended that other medicines are reviewed prior to therapy and the ITP dose is adjusted per clinician's instructions. |
| Moderate or strong dual CYP2C9 and CYP3A4 inducers | Might decrease the exposure to Avatrombopag tablet. | Evaluate all other drugs being taken and modify the ITP dosage when necessary. |
| OTC medicines, supplements and herbal products | Other drugs or substances might interact with avatrombopag 20mg. | It is important to give the healthcare provider the complete list of the drugs you are taking. |
FAQs About Avapag 20mg Tablet
What is the complete brand name of Avapag 20mg Tablet?
Complete name is Avapag 20mg Tablet with active salt "Avatrombopag".
What is the exact amount of strength in each Avapag Tablet?
Each Avapag 20mg Tablet contains has 20mg of composition which is the active drug component.
In which dosage form is the Avapag 20mg Tablet available?
Avatrombopag 20mg is available in an oral tablet form.
What are the uses of Avapag 20mg?
Avatrombopag tablet is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure and chronic immune thrombocytopenia in patients with inadequate response to prior therapy in the indicated setting.
What does Avapag 20mg Tablet do?
Avatrombopag 20mg tablet acts as a thrombopoietin receptor agonist on megakaryocytes. It increases platelet production. It does not replace platelet transfusion.
How should patient take Avapag 20mg Tablet?
In the case of chronic liver disease, the dose varies according to platelet count – if it is below 40 × 10⁹/L, it will be 60mg once daily for 5 days, and if it is between 40 to 50 × 10⁹/L, it will be 40mg once daily for 5 days. This drug is generally administered 10-13 days before the procedure. With regard to chronic ITP, administration usually starts at 20mg once daily with food.
What are some of the common side effects?
Some of the common side effects might be headaches, fatigue, nausea, and abdominal pain. With chronic ITP, bruising and infection are other possibilities.
What are the important precautions?
Avapag 20mg Tablet can lead to an increased risk of thrombotic/thromboembolic side effects such as portal vein thrombosis. Platelets should not be deliberately normalized.
What tests or monitoring are required while using this medication?
Platelet counts are measured before initiation of therapy and before procedures in chronic liver disease. In chronic ITP, platelet counts are usually measured once a week until the platelet count is stabilized, thereafter monthly, and weekly for 4 weeks following discontinuation of treatment. Health care providers monitor for signs of blood clots.
Can I switch to another product that works like Avapag 20mg Tablet?
No. A healthcare professional must confirm first the suitability of the drug based on its active ingredient, strength, and dosage form.
References
- DailyMed. Avatrombopag Prescribing Information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2d5960d-6c18-46cc-86bd-089222b09852
- European Medicines Agency (EMA). Doptelet (avatrombopag) – Product Information https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet
- European Medicines Agency (EMA). Doptelet – Medicine Overview https://www.ema.europa.eu/en/documents/overview/doptelet-epar-medicine-overview_en.pdf
- Terrault N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.Gastroenterology. 2018 https://pubmed.ncbi.nlm.nih.gov/29778606/
- American Society of Hematology. Evidence-Based Management of Immune Thrombocytopenia: ASH Guideline Update.Hematology, ASH Education Programhttps://pubmed.ncbi.nlm.nih.gov/30504359/
Marketer Details
Everest
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
